Analysis of efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantation

Analysis of efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantation - Triple therapy for posttransplant hepatitis C

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009171

Enrollment

Registered

2012-10-23

Start date

2012-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis C after liver transplantation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Recurrent hepatitis C after liver transplantation 2. HCV genotype 1 3. 20 years old and over 4. Possible to come to Kyoto University Hospital during the treatment 5. Written informed consent for participation in this study is obtained

Exclusion criteria

Exclusion criteria: without abilty to understand informed consent

Design outcomes

Primary

Measure	Time frame
Efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantation	—

Countries

Japan

Outcome results